Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease

Patients with chronic kidney disease (CKD) develop anemia largely because of inappropriately low erythropoietin (EPO) production and insufficient iron available to erythroid precursors. In four phase 3, randomized, open‐label, clinical trials in dialysis‐dependent and non–dialysis‐dependent patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Koury, Mark J., Agarwal, Rajiv, Chertow, Glenn M., Eckardt, Kai‐Uwe, Fishbane, Steven, Ganz, Tomas, Haase, Volker H., Hanudel, Mark R., Parfrey, Patrick S., Pergola, Pablo E., Roy‐Chaudhury, Prabir, Tumlin, James A., Anders, Robert, Farag, Youssef M. K., Luo, Wenli, Minga, Todd, Solinsky, Christine, Vargo, Dennis L., Winkelmayer, Wolfgang C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543410/
https://www.ncbi.nlm.nih.gov/pubmed/35751858
http://dx.doi.org/10.1002/ajh.26644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543410/
https://www.ncbi.nlm.nih.gov/pubmed/35751858
http://dx.doi.org/10.1002/ajh.26644

Ejemplares similares